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Abstracts of invited papers
Radiobiological characteristics of human tissues in vivo -
data from the CHART study
Professor Ann Barrett on behalf of the CHART Steering
Group
The CHART (Continuous Hyperfractionated Accelerated
Radiation Therapy) trials in head and neck and non-small
cell carcinoma of the bronchus, which began in January
1990, closed in March 1995 when 918 and 563 patients
respectively had been accrued. Patient characteristics were
balanced between the treatment groups and protocol
treatment was given in 89% of cases. Early mucosal
reactions occurred sooner with CHART and were more
troublesome than with conventional therapy. They settled
quickly and so far no difference in long-term morbidity has
been observed. L'hermitte's Syndrome has been observed in
11 patients in both arms of the study. There has been no
radiation myelitis. There has been a 10% improvement in
survival in the bronchus trial and a small statistically non-
significant improvement in disease free interval in the head
and neck patients. In both trials there is a trend for those
with more advanced disease (T3 and T4) to benefit more
from CHART. Interim results appear to confirm the
hypothesis that tumour cell repopulation may occur during
treatment and the treatment should therefore be completed
in the shortest possible overall time. The implications of this
for normal tissue reactions will be discussed. Detailed data
on early and late normal tissue reactions will be presented
and the use of this data for further hypothesis testing will be
discussed.
Quantifying subclinical metastatic burden and its response to
elective treatments
H Rodney Withers, MD, DSc
Radiation Oncology and JCCC, UCLA, Los Angeles, CA
90095-1714, USA.
Although no patient is cured of cancer if the primary tumor
is not controlled, a major improvement in survival has
stemmed from elective treatment of subclinical disease as an
adjuvant to curative treatment of the primary. Historically
this began with elective radiotherapy of regional disease and
was later extended to chemotherapy for systemic metastases.
By definition, the quantitative assessment of the extent of
metastatic subclinical disease is impossible, and appropri-
ately, elective treatment is usually based on an implicit
assumption that patients at risk harbor a maximal metastatic
cell burden.
If for a certain type and stage(s) of cancer a proportion of
patients have overt (clinically detectable) metastases at
presentation, and a proportion will never develop metastases
if the primary tumor is controlled, then the remainder, that
is, the proportion who show no evidence of metastases at
presentation but who will subsequently develop them, can be
assumed to harbor a metastatic cell burden distributed
between 1 and N, where N is the number of metastatic
tumor clonogens necessary to become detectable. Because of
an exponential growth pattern of metastases and a wide
variation among patients in the size of the primary at the
time of initiation of metastases, a reasonable first assumption
is that there was a uniform distribution of the logarithm of
metastatic cell numbers among patients with subclinical
metastases. The dose response of subclinical disease is
consistent with this assumption leading to the possibility of
analyzing the biological basis for the dose responses of
subclinical metastases.
This investigation was supported by PHS grant
number CA-31612 awarded by the National Cancer
Institute, DHHS.
Hazards of ionizing radiation: 100 years of observations on
man
R Doll, ICRF/MRC/BHF
Clinical Trial Service Unit & Epidemiological Studies Unit,
Department ofMedicine, Radcliffe Infirmary, Oxford OX2
6HE.
100 years ago, when R6ntgen discovered x-rays, epidemiology
was effectively limited to the study ofinfectious disease and the
hazards ofionizing radiation were initially discovered through
clinical acumen and laboratory experiment. Such methods
quickly led to the recognition of acute effects and gradually
over 50 years to the recognition that ionizing radiation could
also produce genetic mutations, chronic anaemia, and cancers
in many sites. Cancer, however, was generally thought to be
produced only when the dose was large enough to cause
macroscopic tissue damage. An occupational hazard of
leukaemia alone gave cause to think that cancer might also
be produced by the accumulation of small doses.
Following the explosion of the atomic bombs the situation
changed and attempts began to be made to obtain
quantitative estimates of risk, and it was not until after the
explosion of the hydrogen bomb in 1954 that they were
organized in such a way as to enable small risks to be
estimated effectively. The results now available from many1014
sources relating to genetic mutations, damage to the fetal
brain, the risk of cancer, and an increased rate of ageing are
reviewed and their limitations discussed.
Release of sitric oxide by huan ocytes/ bg
S Moncada
The Wellcome Research Laboratories, Langley Court,
Beckenham, Kent BR3 3BS.
The formation of nitric oxide (NO) from L-arginine is now
recognised as a ubiquitous pathway involved in a variety of
physiological functions. The synthesis of NO by vascular
endothelium is responsible for the vascular tone that is
essential for the regulation of blood pressure. In the central
nervous system NO is a neurotransmitter that underlies a
number of functions, including the formation of memory. In
the periphery, there is a widespread network of nerves,
previously recognised as nonadrenergic and noncholinergic,
that operate through an NO-dependent mechanism to
mediate some forms of neurogenic vasodilatation and
regulate various gastrointestinal, respiratory, and genitour-
inary tract functions. Nitric oxide also contributes to the
control of platelet aggregation and the regulation of cardiac
contractility. These physiological effects of NO are all
mediated by the action of a constitutive NO synthase and
subsequent activation by NO ofthe soluble guanylate cyclase.
In addition, NO is produced in large quantities by an
inducible NO synthase (iNOS) during host defence and
immunological reactions. Because it has cytotoxic properties
and is generated by activated macrophages, NO is likely to
have a role in nonspecific immunity. Indeed, mice in which
the iNOS gene has been disrupted show increased suscept-
ibility to parasite infection as well as reduced non-specific
inflammatory responses. The induction of iNOS has recently
been demonstrated in human monocytes/macrophages
following expression and ligation of the low affinity receptor
for IgE. The induction of iNOS correlates directly with the
intracellular killing of Leishmania major by these cells. Nitric
oxide produced by iNOS is involved in the pathogenesis of
conditions such as septic shock and perhaps also the
hyperdynamic state of cirrhosis and in inflammation. Recent
observations have shown that the generation of NO in
human breast cancer correlates positively with tumour grade.
It has also been shown that tumours from a human tumour
cell line, genetically engineered to generate NO continuously,
grew faster and were more vascularised than those from wild-
type cells. However, the NO-generating cells grew more
slowly in vitro than did the wild-type cells, suggesting that
NO may have a dual pro- and anti-tumour action, depending
on the local concentration of the molecule.
Mecaim of tumour s _igeei
Roy Bicknell, Adrian L Harris, Hua-Tang Zhang and
Rangana Choudhuri
Molecular Angiogenesis Group, Imperial Cancer Research
Fund, Institute ofMolecular Medicine, University ofOxford,
John Radcliffe Hospital, Oxford, OX3 9DU.
Recent studies from several groups have shown a strong
correlation between the vascular density of primary human
tumours (eg breast) and metastasis. Thus, vascular density
has become a significant new marker of prognosis. In highly
vascularised tumours the vessel dense areas appear as
localised hot spots. Screening of angiogenic factor expression
in primary human breast tumours has identified those factors
most commonly excpressed or over-excpressed in tumours
relative to normal breast tissue.
The effect of expression of angiogenic factors on the i
vivo growth of the human MCF-7 breast carcinoma line has
been examined. MCF-7 cells were chosen because when
xenografted into nude mice they form (i) slow growing, (ii)
poorly vascularised, (iii) oestrogen dependent, (iv) tamoxifen
sensitive tumours that (v) do not metastasise. Thus, the
transfection of any one gene into these cells permits an
evaluation of the effect of the expression of the gene
product on each of these properties. The effect of
transfection of the angiogenic peptides vascular endothelial
growth factor, platelet-derived endothelial cell growth
factor/thymidine phosphorylase, midkine and pleiotrophin
will be described.
Tumour perfuson, oxygention status, pH
ditributon, and energ statu
Peter W Vaupel
Institute ofPhysiology & Pathophysiology, Univ ofMainz,
Duesbergweg 6, D-55099 Mainz, Germany.
It is generally accepted that tumor perfusion, microcircula-
tion, the tissue oxygenation status, pH distribution, and the
bioenergetic status - factors which are usually closely linked
and which define so-called metabolic microenvironment - can
markedly influence the biological behavior of malignant
tumors such as the invasive and metastatic potential, the
malignant progression, and the heterogeneity of the cellular
phenotype. Furthermore there is clear indication that the
early reponses to tumors to standard radiation, chemother-
apy and other non-surgical treatment modalities, long term
outcome and diagnostic measures can also be greatly
modulated by the relevant factors of the metabolic
micromilieu.
Currently available information on the following para-
meters in human tumors will be presented:
1. tumor vasculature and blood flow,
2. tumor oxygen supply and tissue oxygenation,
3. tissue pH distribution, extracellular vs. intracellular pH,
and
4. metabolic and bioenergetic status.
According to these data, significant variations in these
relevant factors are likely to occur between different locations
within a tumor, and between tumors of the same grade and
stage. Considering these variabilities it might be possible to
characterize individual tumors before therapy in order to
fine-tune treatment protocols.
References
VAUPEL Petal. (1989). Cancer Res., 49, 6449-6465.
VAUPEL P, (1990). Strahlenther. Onkol. 166, 377 -386.
VAUPEL P. (1992). NMR Biomed., 5, 220-225.
VAUPEL PW. (1994). Lecture 23, Berlin Ernst Schering Res.
Foundation.
Hypoxia in tnours - a physolocal abnormalty that can be
exo6fed
U Stratford', L Griffiths', G Dachs', A Patterson-2,
M Saunders', E Chinje', R Bicknell2 and A Harris2
'Medical Research Council, Harwell, Oxfordshire OXJJ ORD,
21nstitute ofMolecular Medicine, John Radcliffe Hospital,
Oxford 0X3 9DU.
It has long been known that the presence of hypoxia in solid
tumours can be a critical factor in determining resistance to
radiation and cytotoxic drugs. However, this physiological
abnormality is potentially excploitable to provide a selectivity
for drug activation that would not otherwise be possible.
Three excamples are given below.* Recently it has been shown that hypoxia can stimulate
the production of VEGF with the consequent induction of
angiogenesis in a range of tumour types. Another angiogenic
growth factor regulated by hypoxia is PDECGF (platelet
derived endothelial cell growth factor, a TP-thymidine
phosphorylase). We have shown that levels of PDECGF
protein are increased 7-fold in MDA 231 cells in vitro
following culture at 0.3% 02 for 16 h. Immunohistochemical
staining of MDA 231 tumours show increased expression of
PDECGF in those parts of the tumour that are proximal to
areas of necrosis. Further, increased, uniform expression of
PDECGF is obtained if the tumour vascular supply is
occluded for 2 h. Since PDECGF has TP activity, the
hypoxia induced up-regulation is potentially exploitable, e.g.
in the use of furtulon which is converted to 5-FU by TP.
* Hypoxia regulated proteins such as VEGF have DNA
sequences adjacent to their coding regions that bind the
nuclear transcription factor HIF-1. DNA constructs have
been prepared that encode the CD2 surface protein and
cytosine deaminase under transcriptional control of promo-
ters containing the PGK-1 hypoxia responsive element
(HRE). These were stably transfected into HT1080 cells
and the proteins shown to be up-regulated following hypoxic
exposure in vitro. Treatment with 5-FC which is converted to
5-FU by cytosine deaminase was considerably more toxic
towards cells previously exposed to hypoxia compared to
aerobic cells. Further, growth of transfected HT1080 cells as
tumours in vivo showed focal expression of CD2 in the
hypoxic cells in the tumour. Thus, HREs could be useful for
application in tumour specific gene therapy.
* Hypoxia provides a unique environment for the
activation of bioreductive drugs. This process is also
mediated by the presence of appropriate reductases. It has
previously been shown, using a panel of breast cancer cell
lines, that cytotoxicity of tirapazamine is dependent upon the
expression of P450 reductase (P450R). MDA 231 cells have
been stably transfected with P450R to give a panel of six
clones. In the panel the hypoxic toxicity of tirapazamine and
RSU1069 varies 10-fold and toxicity correlates positively with
P450R activity.
These results indicate that not only can hypoxia in
tumours be exploited for cell killing but this can, in
addition, be enzyme directed.
Current status of high-dose chemotherapy in metastatic breast
cancer
John Crown
St Vincent's Hospital, Dublin 4, Ireland
If the activity of a chemotherapeutic regimen is defined in
terms of its ability to produce complete remissions, then
chemotherapy administered in the dose range which requires
autologous stem cell support (HDC), is the most active
treatment currently available for metastatic breast cancer
(MBC). In single arm studies HDC yielded CR rates of
approximately 50% in previously untreated patients. These
historically-controlled trials also suggest that patients who
were treated with HDC had superior disease-free survival
compared to patients who had received conventionally-dosed
chemotherapy (CDC), and furthermore, that a proportion
achieved such atypically durable remissions, that they might
be cured. Valid arguments have been advanced that these
results were artefacts of case selection and responsiveness to
prior CDC, however the recent randomized trial of Bezwoda
et al has provided some confirmation of these data. In this
study, patients with chemotherapy-naive MBC were treated
with two cycles of HD mitoxantrone, VP16 and cyclopho-
sphamide. Patients in the HDC arm had superior response,
complete response, survival and durability of remission.
While this trial has been criticised on the grounds that the
CDC arm did poorly, the most important fact to emerge
BACR/ACP/BOA Abstracts
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from this work is not the superiority of the HDC arm, but
rather the confirmation that the results of the single arm
studies of HDC were essentially accurate. In addition, the use
of HDC without prior CDC is consistent with the theory that
the 'CDC-induction/HDC consolidation' model for HDC
represents a somewhat anachronistic interpretation of the
Norton-Simon Hypothesis, which in fact argues for
intensification and acceleration throughout therapy.
Many investigators believe that confirmatory trials are
now the major priority. The results of HDC in high risk stage
II breast cancer are sufficiently promising to justify wide-
spread testing in randomized trials, e.g. the Anglo-Celtic
Oncology Group Study. In MBC however, the failure of very
high rates of CR to translate into higher rates of durable
remission suggests that further developmental work should
retain a high priority.
As the treatment for other chemo-curable cancers involves
multiple, timely applications of effective therapy, and as the
most effective therapy for MBC is HDC, then the systemic
study of accelerated multi-cycle HDC seems logical. The
introduction of the new haemotopoietic support technologies
has made this approach feasible, and preliminary studies in
Memorial Sloan-Kettering indicate that it is particularly
active, producing extremely high rates of complete remission,
but at the cost of severe toxicity. Other approaches include
consolidative immunotherapy for patients in CR. The
question of tumour cell contamination of the autograft
product will likely become increasingly important if the HDC
regimens become more efficient at eradicating disease in vivo.
Approaches involving positive selection of haematopoietic
progenitors may be particularly promising in this regard.
Abstracts of members' proffered
papers
1.1 The influence oftransforming growth factor #3 (TGF,B3) on
the radiation responses ofnormal and malignant colonic cell lines
H Robson', K Spence', J Hendry2, E Anderson' and
C Potten3
'Clinical Research Dept, Christie Hospital NHS Trust;
2Experimental Radiation Oncology and 3Epithelial Biology,
Paterson Institutefor Cancer Research, Manchester M20 4BX.
In colorectal cancer it is clear that the timing of adjuvant
radiotherapy in relation to surgery influences the outcome in
terms oflocal recurrence and overall survival (Erykholm et al.,
1993, Dis. Colon andRectum, 36:564-572). The biological basis
for this effect may be related to the inflammatory and wound
healingresponses induced by cytotoxic therapy and the surgical
insult. Both involve the local release ofcytokines and growth
factors. The effects of TGF,B3 on the radiation sensitivity of
normal and malignant colonic cell lines has been investigated
with the aim ofincreasing the therapeuticratio between tumour
response and normal tissue damage.
A clonogenic assay was used to measure the radiation
sensitivity of monolayer, exponentially growing cultures of
human colonic tumour cell lines (Widr and HT29) and a
normal rat intestinal cell line (IEC6) both with and without a
6 h post-irradiation delay to allow for repair of potentially
lethal damage. TGF#3 (5 ng ml-1) was added to the cultures
either before, during or after irradiation. Treatment with
TGF/3 for 24 h before irradiation significantly increased the
radiosensitivity of the Widr cell line only when they were
allowed the 6 h recovery period. The same protocol had no
effect on the radiosensitivity of the HT29 cell line but was
able to reduce the radiosensitivity of the normal cell line,
IEC6. These are indicated as the surviving fraction (SF) at
7.5 Gy in the table below. Flow cytometric cell cycle analysis
at all stages of the experiment showed that the number ofB A/ACP/BOA Asract
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IEC6 cells in S-phase was considerably reduced by the pre-
irradiation treatment whereas there was no effect on the
malignant Widr cells. The results suggest that the effects of
TGF#3 on the radiation sensitivity of normal colonic cells
may be related to its effects on cell cycle. However, the
possibility that TGF#3 may have separate effects on DNA
repair mechanisms is also being investigated.
Cell line IEC6 HT29 WIDR
Control (SF 7.5 Gy) 26.5+0.72 12.8+0.7 20.1 +0.3
+TGF#3 (SF 7.5 Gy) 35.6+0.90 12.0+0.7 13.6+0.3
1.2 Measrement of crvical carinoma proliferation rate to
predict radioteapy respone
BS Bolger', RP Symonds*2, PD Stanton3, TG Cooke3, R
Burnett4
Dept. ofGynaecology, 2Oncology, 3Surgery and'Pathology,
University ofGlasgow, Western Infirmary, Dumbarton Road,
Glasgow GIl 6NT.
Estimation of tumour proliferation may allow the design of
individualised radiotherapy schedules to optimise response.
This prospective study correlates the tumour proliferation
rate of cervical carcinoma with response to conventional
radiotherapy. The potential tumour cell doubling rate (Tpo)
was estimated following flash labelling of the tumours in vivo
using the DNA precursor Bromodeoxyuridine (BrdUrd),
samples were analysed by flow cytometry. Tumour ploidy,
DNA index and mitotic count were also assessed as was
histological grade and type.
Multiple biopsies from each tumour were obtained from
121 women. The median Tpt was 4.0 days. More rapid
proliferation was seen in association with advanced clinical
stage (P=0.01). Higher BrdUrd labelling was seen im
association with pelvic tumour recurrence, this was the only
biological/histological parameter with univariate and multi-
variate significance in relation to loco-regional recurrence
(P=0.006 and P=0.034 respectively).
This study represents the first assessment ofTpi, in relation
to radiotherapy treatment response of cervical carcinoma.
The association ofrapid proliferation and poor pelvic disease
free survival indicates the need for further research into the
potential of radiotherapy schedule alteration to reflect
tumour proliferation. The predictive value may be enhanced
by combination with other biological parameters.
1.3 Stable bioenergetic statu during severe hypoxia in a moue
M Nordsmarkl*, RJ Maxwell2, MR Horsman' and
J Overgaard'
'Danish Cancer Society, Dept. ofExperimental Clinical
Oncology', Centrefor Magnetic Resonance, Aarhus University
Hospital, Denmark.
Backgroud Hypoxic cells in solid tumours are known to be
relatively radioresistant (1,2). Therefore several attempts to
identify radiobiological hypoxia have been suggested, among
these P02 electrode estimates of oxygenation status and 31P
MR Spectroscopy (31P MRS) (3-4). Recent studies have
however questioned the susceptibility ofenergy measurements
as indicator of hypoxia (5-7). We here report results of gas
breathing induced changes on tumour p02 and energy status.
Materials and meto: A C3H mammary carcinoma grown
in the feet of CDF1 mice was used. Non-anaesthetized mice
were restrained and allowed to breath either 100% oxygen,
carbogen (95% 02+ 5%C02), carbon monoxide (GO) at
660 p.p.m. or atm. air for 64 min. Bioenergetic status was
measured continuously by 31P MRS (7 Tesla SISCO
spectrometer) and evaluated as beta nucleosidetriphosphate/
inorganic phosphate (f-NTP/Pi) ratio. Tumour oxygenation
was measured polarographically (Eppendorf, Germany) after
either 16 or 45 min and evaluated as the percentage of
PO2,5 mmHg.
Resoht: Carbogen and 100% oxygen breathing resulted in a
continuous and significant increase in the P-NTP/Pi ratio. This
was compatible with the reduction in hypoxia from 61% to 32
percent of PO2,5 mmHg respectively. Breathing of CO
660 p.p.m. however, increased the percentage of
PO2 5 mmHg from 61 to 94%, whereas the f-NTP/Pi ratio
was stable over 64 min.
Conchnsow Tumour cells in vivo were able to maintain the
bioenergetic status during a period of at least 1 h of severe
hypoxia - almost equivalent to the level of oxygenation
achieved by clamping ofthe blood supply.
Referecs
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2. OVERGAARD. (1989). Int. J. Radiat. Oncol. Phys., 56, 801.
3. KALINOWSKI. (1990). Int. J. Radiat. Oncol. Phvs., 19, 953.
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7. NORDSMARK. (1995). Acta Oncol., 34(3), 329.
Supported by a grant rom the Danish Cancer Society.
1.4 Comparison ofeffects of iconamide and pentoxifyfw on
RIF-1 tu_mo oxygeation
DJ Honess*, MS Andrews and NM Bleechen
Univ. and MRC Dept. of Clinical Oncology, Hills Rd,
Cambridge, CB2 2QH, UK.
Pentoxifylline (PXF) and nicotinamide (NCT) are effective
radiosensitisers of murine tumours which act by increasing
tumour P02. NCT is known to reduce intermittent hypoxia
and PXF appears to act similarly. We have studied their
effects on the 600 mm3 RIF-l tumours with the aim of
comparing the magnitude and time course of the effects of
both agents. The P02 distribution was measured with the
Eppendorf 6650 histograph system with a 0.7 mm net
forward step for each reading, 50-60 readings per tumour
and 10-12 tumours per group. The P02 distribution is highly
skewed to the lower values and was described by the median
and the percentage of values <2.5 mmHg, i.e. those thought
to represent biologically relevant hypoxia. Control medium
P02 was -1 mmHg, with - 80% values of <2.5 mmHg.
Maximum increases in p02 after PXF were at 15 min after
20 mg/kg PXF (mean+2SE of median: 15+2 mmHg; mean
of % <2.5 mmHg: 19+3 and after NCT were at 1 h after
250 mg/kg NCT medium 24+3 mm Hg, 7±3%
<2.5 mmHg). The half-times for decay of these changes
(t[pO2],) were calculated from P02 measurements at
appropriate times after the peak effect. PXF t(pO2J%. was
4.3 (3.4-5.9) min for the median value which corresponds
closely with the plasma half-life (ti) of PXF, 4.6 (4.2-2.1) min
but t[pO],0 was significantly longer for the % <2.5 mmHg at
9.9 (7.3-15.5) min. NCT t[pO2],', was 3.2 (2.4-5.0) h for the
median value, slightly longer than the plasma t., of NCT i.e.
2.2 (2.0-2.4) h and again was significantly longer for the %
<2.5 mmHg at 9.4 (6.3-19.2) h. The fact that t[pO2J' for
median values for both drugs was comparable with plasma tls
was consistent with the requiirement for the drug to be
present for p02 modification. It follows that the longer the
drug availability, the greater the likely magnitude of p02
change. The greater effect on p02 by NCIT than PXF could
therefore be attributable to its longer plasma tl,. This
hypothesis was tested by prolonging the plasma availability
of PXF by giving 20mg/kg followed by 2xl10mg/kg atBACR/ACP/BOA dacts
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10 min intervals (40 mg/kg in all), and measuring P02 15 min
after the final dose. The p02 increase (median 21 +2 mmHg,
8+3% <2.5 mmHg) was larger than that for 40 mg/kg as a
single dose (median 15+2 mmHg, 16+4% <2.5 mmHg)
which is isoeffective with 20 mg/kg as a single dose (median
15+InInHg, 17+4% <2.5 mmHg). These results are
consistent with the hypothesis. The half-times for decay of
the effect of the prolonged PXF dosing were measured and
t[PO21¼/ was increased to 10.0 (7.3-15.5) min for median
values and to 15.0 (12.1-20.0) min for % <2.5 mmHg. We
conclude that extending the drug availability increases the
magnitude of the p02 increase and prolongs the t[pO21h,/ for
the % <2.5 mmHg.
1.5 The effect ofcarbogen brthing on intra- and extraceliular
pH and lactatel in rat bepatomas
M Stubbs*, SP Robinson, LR Rodrigues and JR Griffiths
Cancer Research Campaign Biomedical MR Research Group,
Division ofBiochemistry, St George's Hospital Medical School,
London SWJ7 ORE, UK.
It has been known for many years that tumours produce
large amounts of lactic acid and recently it has been shown
that the intracellular pH (pHi) of rodent tumours is higher
than that of the tumour extracellular fluid (pH), in contrast
to normal tissues (e.g. liver) in which pHi is lower than pH,
(Stubbs et al., 1994 Cancer Res., 54, 4011). We have used
carbogen (95% 02/5% C02) breathing to alter the tumour
environment to study the relationship between pHi, pH. and
[lactate] in vivo in Morris Hepatoma 9618A grown
subcutaneously in rats. Measurements of blood pCO2, p02,
pH and HCO3-, were made by conventional analyses whereas
pHi and pHM (using 3-aminopropyl phosphonate as an
extracellular marker) of the hepatomas were made by 31p
Magnetic Resonance Spectroscopy followed by lactate
measurements on tissue extracts. When hepatomas in normal
air-breathing animals were compared to hepatomas from
carbogen breathing animals the following was observed:
lactate
pHi pHe pUmol/gm
Time ofbreathing carbogen (n=4) (n=4) (n=2-3)
0 min 7.00+0.17 6.79+0.04 4.9+0.9
30 min 6.99+0.17 6.44+0.20 2.0
These findings are interpreted in terms of the regulation of
intracellular pH in tumours and show that even in the
presence of large amounts of CO2, pHi is maintained neutral
by the tumours with compensating changes in other ions or
compartments.
1.6 Tuno_r P02 predicts radiation respoe in mie an men
MNordsmark*I, M Overgaard2, MRHorsman', JOvergaard'
'Danish Cancer Society, Dept. Experirnental Clinical Oncology
and 2Dept. Oncology, Aarhus University Hospital, Denmark.
There is substantial evidence that hypoxic tumour cells
compromise the effect of irradiation (1,2). In this report
oxygenation status (tumour p02) was correlated with
radiation response in 108 C3H mouse mammary carcinomas
and in 36 patients with advanced squamous cell carcinomas
of head and neck. Tumour p02 was measured by
polarographic oxcygen electrodes (Eppendorf, Germany) and
evaluated as the median PO2, the percentage of PO2 values
S2.S mmHg and S mmHg. In mice group one (n = 52)
tumour p02 was hypothesized to predict outcome of
radiation response. The median value of the three oxygena-
tion parameters was related to the probability of tumour
control after 55 Gy single dose and tumour control showed
to be significantly lower among the 26 most hypoxic tumours.
In mice group two (n=56) the hypothesis was tested and
fulfilled, the percentage ofP02 values <2.5 mmHg being the
dominating parameter among the three in question. This
endpoint was subsequently chosen for evaluation of the
clinical data. Patients were treated by conventional external
radiotherapy 66-68 Gy in 33-34 fractions. 16 patients had
locoregional tumour recurrence. Among these 16 patients the
median of the percentage ofp02 values <2.5 mmHg was 30
(range 0-95%) as compared to the 20 patients without failure,
who had a median of 6 (range 0-51%). When separating all
36 patients by the median of the percentage of p02 values
<2.5 mmHg and comparing the actuarial tumour control at
2 years using Kaplan-Meier estimates the most hypoxic part
had significantly lower tumour control (p<0.014, Logrank
test). Also by Cox multivariate analysis the percentage ofP02
values <2.5 mmHg as continous variable was found to be
significant (p=0.0065). In conclusion these results suggest
that tumour oxygenation is predictive of radiation response.
References
1. MOULDER JE et al. (1984). Int. J. Radiat. Oncol. Phis., 10, 695.
2. OVERGAARD J. (1989). Int. J. Radiat. Oncol. Phvs., 56, 801.
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1.7 Adjuvant intaperitoneal radionnunamot1erapy of ovarian
cancer: a case-control report ofphase H survival
S Nicholson*', C Gooden', V Hird2, P Mason2 and
AA Epenetos'
'ICRF Oncology Unit, Hammersmith Hospital, W12 OHS,
2Dept. ofGynaecology, Sammaritan Hospital, London.
Overall survival for advanced ovarian cancer remains poor,
in spite of complete remission being obtained following
debulking surgery and platinum-based chemotherapy. 25
patients received single-dose intraperitoneal radioimmu-
notherapy with yttrium-90-labelled HMFG1 murine mono-
cloncal antibody, all in the adjuvant setting, i.e. once disease-
free following chemotherapy.
We have sought to provide a meaningful assessment ofthe
long-term survival of these patients by conducting a case-
control study, with controls being drawn from the database of
the North Thames Ovary Group. Controls were matched to
cases on the basis of FIGO stage, age, histological grade and
histological subtype. Where perfect matches could not be
found, controls were selected with the best availableprognostic
variables. Closely-matched controls were found for 20 cases.
Survival at 5 years is 80% for cases compared to 55% for
controls (p=0.0335). Median follow-up is 59 months for
cases compared to 27 months for controls. Median survival
has been reached for neither group.
This treatment is now in Phase III trial. We would
welcome referral of all eligible patients.
1.8 lhe morpbology of esenteric arteries is altered
in the presnce of liver tamour in the rat
AM Wood*, MA Spence, WJ Angerson and TG Cooke
University Dept. Surgery, Glasgow Royal Infirmary, Glasgow
G31 2ER.
The presence of hepatic tumour in both patients with
colorectal liver metastases and in rat models of liver tumour
is associated with derased portal venous blood flow and
incrse splanchnic vascular resistance (Leen E et al. Br. J.
Swrg., 1993; 80, 1249; Hemingway DM et al. Br. J. Surg.
1991; 78, 326). These changes are due, at least in part, to theBACR/ACP/BOA Abstracts
presence of a circulating vasoconstrictor (Carter R et al. Br.
J. Cancer, 1994; 69, 1025). To determine whether these
haemodynamic changes are also associated with structural
changes in splanchnic vessels, we have measured wall
dimensions in mesenteric resistance arteries from rats with
and without hepatic tumours. The small bowel was isolated
and harvested 23-28 days following intra-hepatic inoculation
of either HSN sarcoma cells or a control solution and
perfused via the superior mesenteric artery at 90-100 mmHg
pressure, using a 2.5% buffered glutaraldehyde solution. The
samples, taken from 13 tumour-bearing and 13 control rats,
were coded so that the measurements could be performed in
a blind manner. Tissue blocks were embedded in wax and
sectioned so that the vessels of interest were cut in transverse
section. The vessels were stained with haematoxylin and eosin
and viewed using an image analysis system which allowed
lumen diameter as well as median and wall thickness to be
measured. Average media-to-lumen and wall-to-lumen ratios
were calculated for each animal and compared for each group
using a Mann-Whitney U test. Results are expressed as
median value (interquartile range).
Tumour Control p
Media-to-lumen ratio 0.062 (0.052 -0.086) 0.048 (0.042-0.060) 0.031
Wall-to-lumen ratio 0.125 (0.105-0.174) 0.090 (0.075-0.135) 0.031
Media-to-lumen and wall-to-lumen ratios were signifi-
cantly increased in tumour-bearing animals compared with
controls, demonstrating that the presence of liver tumour
can alter the structure of extrahepatic blood vessels. These
findings are consistent with the changes in splanchnic blood
flow which occur in vivo in liver cancer. Ongoing studies
will determine whether increased wall thickness is due to
smooth muscle hyperplasia or hypertrophy or to vessel
remodelling.
1.9 Tumour angiogenesis in NSCLC
KJ O'Byrne, MI Koukourakis, A Giatromanolaki,
R Whitehouse, DC Talbot, KC Gatter and AL Harris
ICRF Clinical Oncology Unit and Dept. of Cellular Science,
Oxford Radcliffe Trust
Tumor angiogenesis is an important factor for tumor growth
and metastasis. Although some recent reports suggest that
microvessel counts in non small cell lung cancer are related
to a poor disease outcome, the results were not conclusive
and were not compared with other molecular prognostic
markers. In the present study we assessed the vascular grade
in 107 (T1,2-NO,1) operable non small cell lung carcinomas
using the JC70 monoclonal antibody to CD31. Three
different vascular grades were defined with appraisal by
eye and Chalkley counting - high (Chalkley score 7-12),
medium (5-6) and low (2-4) vascular grade. There was a
significant correlation between eye appraisal and Chalkley
counting (p<0.0001). Vascular grade was not related to
histology, grade, proliferation index (Ki67), EGFR or p53
expression. Tumors from younger patients had a higher
degree of angiogenesis (p =0.05). Apart from the vascular
grade, none of the other examined factors was statistically
related to lymph-node metastasis (p<0.0001). A univariate
analysis of survival showed that vascular grade was the most
significant prognostic factor (p =0.0004) followed by N-stage
(p =0.001). In a multivariate analysis, N-stage and vascular
grade were not found to be independent prognostic factors
since both were strongly related to each other. Excluding N-
stage, the vascular grade was the only independent
prognostic factor (p =0.007). Kaplan-Meier survival curves
showed a statistically significant worse prognosis of patients
with high vascular grade. No difference was observed
between low and medium vascular grade. Our data suggest
that angiogenesis in operable non small cell lung cancer is a
major prognostic factor for survival and, among the tested
parameters, is the only factor related to cancer cell
migration to lymph-nodes. We are currently evaluating the
relationship of angiogenesis to Bcl-2, c-erbB-2 and thymidine
phosphorylase expression in NSCLC. The integration of
vascular grading in clinical trials on adjuvant chemotherapy
and/or radiotherapy may substantially contribute to defining
groups of operable patients that would benefit from
cytotoxic treatment.
1.10 A method for the generation of murine monoclonal
antibodies with specificity for rat tumour vasculature
NJ Bradley, CT Baillie and MC Winslet
University Department ofSurgery, Royal Free Hospital
Medical School, Pond Street, London NW3 2QG.
The demonstration of proliferation antigens discriminating
tumour from normal endothelium, implicates tumour
endothelium as a potential target for antibody-mediated
immunotherapy. The aim of this study was to generate
tumour vascular-specific monoclonal antibodies (MoAbs) for
testing in an in vivo tumour system.
A spontaneous transplantable renal carcinoma arising in
the BALB/c mouse (RAG cell line) was grown subcuta-
neously in Chester Beatty Hooded nude rats. The resulting
tumours were implanted subcutaneously or intraperitoneally
in 7 BALB/c mice as 1-3 mm3 fragments (Home Office
approved), inducing an anticipated immune response to the
rat tumour stromal component alone. Tumours were
implanted after rapid freeze/thawing to produce tumour cell
death. Two further tumour implants were performed, at
monthly intervals.
Hybridomas were generated by the method of Kohler and
Milstein. Supernatants were screened for the presence of
antibodies by indirect immunoperoxidase staining on 6 mm
frozen sections of RAG tumour and a normal tissue
multiblock from the nude rat. Three hybridomas produced
antibodies with tumour vascular, with 2 successfully cloned
by serial limiting dilutions. The IgG1 MoAb, 003, has stained
the vasculature in 10 different individual rat tumours with
minimal cross-reactivity in normal tissues, confirming the
potential of this methodology to generate tumour vascular-
specific MoAbs.
1.11 Increased expression of PAI-1 constructs in tumour-
stimulated endothelial cells
SG Martin, PW Hewett, J Carmichael and JC Murray
University ofNottingham Laboratory of Molecular Oncology,
CRC Department of Clinical Oncology, City Hospital,
Nottingham NG5 IPB, UK.
An alternative to the more conventional approach of
targeting toxic agents to tumour cells, is to take advantage
of differences between normal and tumour-associated
endothelium. We are investigating the use of tissue-specific
promoters to target therapeutic genes to tumour-stimulated
endothelial cells. Plasminogen activator inhibitor-l (PAI-1)
plays an important role in maintaining the normal
homeostatic balance in blood and has been shown by in
situ hybridisation to be up-regulated in tumour-associated
endothelium. We initially used RT-PCR to investigate
expression of the PAI-1 gene in human umbilical vein
endothelial cells (HUVEC) and mammary fat microvessel
endothelial cells (HUMMEC) under a variety of conditions.
Expression was down-regulated in quiescent compared to
proliferating endothelial cells. However, PAI-I could be
induced in quiescent HUVEC and HUMMEC cultures byBACR/ACP/BOA Abstracts
exposure to medium conditioned by a number of tumour
cell lines (TCM). We then attempted to transfect HUVEC
with the pOCAT Hind plasmid, containing a 826 bp
fragment of the PAI-I promoter coupled to a CAT reporter
gene (kindly supplied by Dr A Belayew, Katholieke
Universiteit Leuven, Belgium). Of a variety of techniques
used, only electroporation was successful, yielding reprodu-
cible results. A 72 h expression period was allowed following
transfection and HUVEC were cultured in TCM or control
medium for a further 5 h. TCM enhanced CAT production
approximately 3-fold as measured by CAT-ELISA. We are
currently examining the effects of TCM from a range of
solid tumours on HUMMEC as well as HUVEC transfected
with pOCAT Hind.
1.12 Bone mineral density in adults with lymphoma and the
effects of treatment
E Brankin*l, SJ Gallacher2, R Bessent2, M Soukopl,
IT Boyle2
'Dept. ofMedical Oncology, 2University Dept. ofMedicine,
Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31
2ER.
Bone density was measured by DXA (Lunar DPX) at
lumbar spine (L2-4) and neck of femur (NOF) in 19 males
(mean age 41 years, range 18-59) peviously treated by
radiotherapy (n= 5) or chemotherapy (n= 14) for lymphoma
(mean 9.5 years from diagnosis, range 3-15) and compared
with 29 age/sex matched controls. Bone density tended to be
lower at L2-4 at (mean+SEM) 1.180+0.043 g/cm2 versus
1.234+0.016 g/cm2 (p=NS) (median Z-score=0.5, range
- 1.8 to 4.0) and was lower at NOF (0.982+0.033 g/cm2
vs 1.075+0.025 g/cm2, p=0.03, median Z score = -0.03
range - 1.9 to 2.8). A further 9 patients (8 females, mean
age 52 years) were followed prospectively from lymphoma
diagnosis. Over a mean follow-up interval of 19 months L2-
4 fell from 1.112+0.104 g/cm2 to 1.047+0.106 g/cm2
[-4.1+0.9%/year], p=0.008 and NOF from 0.976+
0.080 g/cm2 to 0.913+0.79 g/cm2 [-4.6+1.0%/year], p=
0.0002. Percentage fall/year was greater in these patients at
both L2-4 and NOF than in group of 52 control subjects
(-0.6+0.3%, p=0.001 and -0.3+0.3%, p=0.004 respec-
tively). These results suggest patients with lymphoma are at
risk of accelerated bone loss around the time of diagnosis
after treatment of lymphoma and of osteoporosis in later
years.
2.1 Familial predisposition to both male and female germ cell
tumours?
RA Huddart*l 2, CThompson', EJ Nicholls2, A Horwich2 and
R Houlston'
'Institute of Cancer Research, 15 Cotswolds Road, Belmont,
Surrey SM2 SNG and 2The Royal Marsden Hospital, Downs
Road, Sutton, Surrey.
A minority of testicular teratomas are recognised to be
familial [Forman et al. Br. J. Cancer 65 p 255-262]. Some
occur as part of the spectrum of cancers in the Li-Fraumeni
syndrome, however, the genetic basis of the majority of
familial cases is unknown. This has prompted the formation
of a Linkage Consortium to identify genes causing testicular
teratomas. As one of the participating centres we have been
ascertaining familial cases from a registry of testicular
teratoma patients at the Royal Marsden Hospitals. Amongst
these cases we have identified 3 families which suggest that a
common genetic basis exists between some male and female
germ cell tumours.
The first family was identified through an index case who
presented with a seminoma at age 51, his brother had had a
testicular teratoma at age 28 and their cousin an endodermal
sinus tumour of the ovary diagnosed at 32. In the second
family the index case presented with an undifferentiated
malignant teratoma at 28 years of age and his sister was
diagnosed with bilateral mature teratomatous cysts at age 39.
In the third family the index case presented with a
retroperitoneal teratoma at 26 and his sister was diagnosed
with an ovarian dysgerminoma at 45. None of these families
had any features indicative of the Li-Fraumeni syndrome or
any other cancer family syndrome suggesting the identifica-
tion of a previously unrecognised association. The 3 families
we report were identified from a database of 2000 teratoma
patients, suggesting that in 0.2% of pedigrees a female
member will develop a germ cell tumour. This may be an
underestimate since pedigree information on all 2000 index
cases has not been verified and many mature teratomatous
cysts are asymptomatic and go undiagnosed.
Whether an association between male and female germ cell
tumours is due to the inheritance of a single gene with effects
on both ovary and testis or a consequence of the action of
modifying genes will only be established when the gene or
genes causing testicular teratomas are identified.
This work is supported by the Cancer Research Campaign
and the Bob Champion Cancer Trust. RAH is supported by
a CRC clinical research fellowship.
2.2 Socioeconomic deprivation and colorectal cancer incidence
in N. Ireland
RH Wilson*', F Kee2, C Patterson2, S Currie3, JM Sloan4, RF
Houston', BJ Rowlands5 and RJ Moorehead5
N. Ireland Centrefor Clinical Oncology', Departments of
Public Health Medicine2, Pathology4 and Surgery5, The
Queens' University ofBelfast, Belfast and IT Department,
Northern Health and Social Services Board3.
Colorectal cancer (CRC) shows a wide variation in incidence
worldwide. Studies of migrant populations suggest that much
of the cross-cultural variation in incidence may be
attributable to environmental factors. Aetiological factors
investigated included diet, sedentary lifestyle, body mass
index and habitual alcohol or coffee consumption. The OPCS
Longitudinal Study did not show a link between CRC
incidence and social factors. N. Ireland has the highest degree
of social polarisation of any region within the UK.
The aim of this study was to determine whether CRC
incidence differed in areas of high and low socioeconomic
deprivation in N. Ireland.
The Northern Ireland Colorectal Cancer Register provided
details on all the 1178 newly-diagnosed patients with CRC in
our province in 1990 and 1991. We related age, sex, site and
Dukes' stage to levels ofsocioeconomic deprivation. Electoral
wards were grouped into quintiles of the population after
ranking by the Townsend Deprivation Score. The association
between CRC incidence and Townsend Score was studied
using Poisson regression analysis.
Age-standardised CRC incidence ranged from 22.5 to 29.9
per 100,000 for men from the least to the most deprived fifth
of the population. The trend for females was similar but
tended to plateau for the lower socioeconomic quintiles. After
adjusting for age and sex, there was a significant association
between CRC incidence and socioeconomic deprivation
(p =0.002). The rate ratio for the most to the least materially
deprived quintile was 1.28 (95% CI 1.06-1.53). The effect
was stronger for rectal (rate ratio 1.09) than colonic cancers
(rate ratio 1.05). There was no statistically significant
difference in the proportion of early and advanced Dukes'
stage tumours between patients from the relatively affluent
and the deprived areas.
We conclude that CRC incidence in N. Ireland is relatedBACR/ACP/BOA Abstracts
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to community deprivation. Further study is necessary to
determine mechanisms for this association.
Keywords: Colorectal cancer, socioeconomic deprivation, cancer
register
2.3 Dose-response study of superficial bladder cancer to
intravesical administration of epirubicin
*'JRW Masters, 2RJM Popert, 2J Goodall, MJ Coptcoat and
3MKB Parmar
'University College London, Institute of Urology and
Nephrology, 3rdFloor, 67 Riding House St, London WIP 7PN,
2Department of Urology, King's College Hospital, Denmark
Hill, London SE5 9RS and 3MRC Cancer Trials Office, I
Brooklands Avenue, Cambridge CB2 2BB.
The aim of this study was to determine if a dose-response can
be observed in the intravesical treatment of superficial
bladder cancer with epirubicin. 100 patients with primary
or recurrent pTa or pT1 disease were treated surgically,
leaving a marker tumour in the bladder. Following
histopathological confirmation of tumour stage, patients
were randomized by the method of sealed envelopes to
receive 1 mg/ml epirubicin (50 mg in 50 ml saline) or 2 mg/
ml epirubicin (100 mg in 50 ml saline) between 10 and 21
days post-operatively. 3 months later the response of the
marker tumour was assessed as complete (no tumour visible
either cystoscopically or histopathologically in a biopsy taken
at the site of the marker tumour) or as no response
(histopathologically confirmed persistence of tumour). The
volume ofthe bladder contents was measured after treatment,
and taking into account dilution by urine the mean doses
received were 0.7 mg/h/ml (1 mg/ml dose) and 1.4 mg/h/ml
(2 mg/ml dose). 43/100 (43%) of the patients responded to
the single instillation of epirubicin. Of the patients receiving
1 mg/ml epirubicin, 22/50 (44%) responded, compared to 21/
50 (42%) of patients receiving 2 mg/ml epirubicin. 5 patients
receiving the higher dose experienced bladder irritability to
the extent that the instillate could not be retained for the full
one hour.
This study does not provide any indication of a dose-
response of superficial bladder cancer to epirubicin.
2.4 Effect of chemotherapy on the inflammatory response in
patients with colorectal liver metastases
HJ Gallagher*', DC McMillan1, A Rumley2, G Lowe2,
TG Cooke1 and CS McArdlel
Departments ofSurgery' and Medicine2, The Royal Infirmary,
Glasgow.
Recent work suggests that the milieu in which the metastatic
cell finds itself is crucial to its survival (Frost P, 1992, Lancet,
339: 1458-1461). It has been reported that many patients
with advanced disease have an ongoing inflammatory
response and there is increasing evidence that this promotes
tumour progression. Hepatic arterial 5FU chemotherapy may
delay or reverse tumour progression in patients with
colorectal liver metastases. However, it may also result in
tissue damage and thus enhance the inflammatory response.
The overall effect on the inflammatory response has not been
demonstrated. This was examined in a cohort ofpatients with
colorectal liver metastases. Patients, of equivalent staging,
were grouped according to whether they had yet received
hepatic arterial 5FU chemotherapy (n = 13) or not (n =8).
Venous samples were centrifuged at 5°C and stored at
-70°C. Plasma viscosity, fibrinogen, fibrin degradation
products (FDP's) and interleukin-6 were measured. Results
are given in median (range). Statistical comparisons were
carried out using the Mann-Whitney U-test.
No chemotherapy Chemotherapy p-value
Plasma viscosity (mPa.s) 1.50 (1.21-1.61) 1.37 (1.21-1.57) 0.17
Fibrinogen (g/l) 4.4 (3.1-6.2) 4.4 (3.2-5.6) 0.310
FDP (ug/i) 602 (118-1032) 144 (75-592) 0.003
Interleukin-6 (pg/ml) 15.7 (1.7-24.7) 3.8 (0.81-24.5) 0.02
There was a significant reduction in interleukin-6 and FDP
concentrations in the patient group who had received
chemotherapy. These results suggest that the contribution
to the inflammatory response from this chemotherapy is
small compared with that of the tumour. It may be that the
changes in such inflammatory markers may provide a method
of predicting response to chemotherapy.
2.5 Peripheral blood progenitor cell (PBPC) rescue following
high dose chemotherapy in breast cancer: satisfactory early
haematopoietic reconstitution
M Eatock*', G Cook2, IM Franklin2, P Tansey2, M Soukop'
and D Dunlop1
Departments ofMedical Oncology' and Haematological
Oncology2, Solid Tumour Transplant Programme, Glasgow
Royal Infirmary University NHS Trust, Glasgow, G4 OSF.
The existence of a dose response relationship in the treatment
of breast cancer is supported by in vitro data and by clinical
data suggesting an increased response rate for patients treated
with high dose chemotherapy. A survival benefit has yet to be
convincingly demonstrated for patients with advanced
disease, however this technique may be useful in the
adjunctive treatment of patients at high risk of relapse
following intital surgery.
14 patients with breast cancer stage II-IV (4 with
metastatic disease and 10 receiving adjuvant therapy for
high risk disease), median age 43 years (range 28-55)
underwent a high dose chemotherapy procedure with PBPC
rescue. Of the 10 patients receiving adjuvant therapy, the
median number of involved axillary lymph nodes was 6
(range 4-11 and all had T2 or T3 tumours).
Induction therapy consisted of cyclophosphamide (Cy)/
Epirubicin (1 patient); 5-fluorouracil/epirubicin/Cy (FEC) (11
patients); doxorubicin (1 patient); doxorubicin followed by
intermediate dose cyclophosphamide (1 patient). A mean of
3.28 x106/Kg (range 1.46-7.75 x106/Kg) CD34+ cells and
121.73 x 104/Kg (range 9.42-305.4 x 104/Kg) CFU-GM
growth were harvested.
7 patients received conditioning therapy with high dose
carboplatin, etoposide and melphalan (CEM), the remainder
received Cy and thiotepa. PBPC rescue was given with a
mean CFU-GM dose of 139 x 104/Kg (range 52.9-268 x 104/
Kg). Median time to neutrophil engraftment (>0.5 x 109/L)
was 11 days (9- 15 days) and median time to platelet
engraftment (>20 x 109/L) was 12 days (6-19 days). Median
in-patient hospital stay following PBPC administration was
19 days (range 15-27 days). Pyrexia was observed in all
patients with a median duration of 6.5 days (4-13 days) and
WHO grade 3 or 4 gastrointestinal toxicity was observed in
10 patients. There were no procedure related deaths in this
group of patients.
Of those patients treated with metastatic disease 3 have
relapsed at 12, 6 and 3 months following PBPC rescue. No
patient receiving adjuvant high dose therapy has relapsed to
date with a median follow up of 14.3 months (5-22 months).
In our experience this is a safe procedure with no
treatment related mortality. Despite encouraging initial
reports of cure rates of up to 25% it remains to be proven
that this type of therapy prolongs survival in patients withBACR/ACP/BOA Abstracts
advanced breast cancer. The role of this treatment in the
adjuvant situation is currently the subject of randomised
trials in Britain and Europe.
2.6 Primary high dose dacarbazine in high grade glioma
AJ Salisbury*l, M Saunders2, AL Harris3, SA Kyrtopoulos4,
AC Jones'
'Radiotherapy Dept., Churchill Hospital, Oxford, OX3 7LJ;
2MRC Radiobiology Unit, Chilton, Didcot, OXJJ ORD;
3ICRF Clinical Oncology Unit, Churchill Hospital; 4Nat.
Hellenic Res. Found., Inst. ofBiol. Res. and Biotech., Athens
11635, Greece.
The prognosis for glioblastoma mutliforme is extremely
poor. Even with surgery and radiotherapy (RT), the
one-year survival is 10-20%. Long term survivors are
rare.
Dacarbazine (DTIC) has been used in the past with a
response rate comparable to the nitrosoureas but at the cost
of greater toxicity, principally vomiting. With the advent of
SHT3 antagonists, the emetic potential of DTIC was greately
curbed. The in vivo activity of dacarbazine is dependent on its
activation to MTIC, which methylates DNA producing o6
and N7 methylguanine. O6-MeG has the major cytotoxic
effect and is repaired by the suicide enzyme 06-alkyl guanine
DNA alkyl transferase (06-AGT). Dacarbazine and temozo-
lamide are converted to the same active metabolite (MTIC).
In view of the promising initial results of temozolamide in
gliomas, it seemed appropriate to investigate the use of
dacarbazine prior to RT in the treatment of high grade
gliomas.
21 patients with glioblastoma multiforme and perfor-
mance status 0-2 received dacarbazine 1 g per m2 as a one
hour infusion every three weeks. Response was assessed
every 2 cycles both clinically and radiologically (CT or
MRI). Patients received a maximum of 6 cycles of
dacarbazine prior to RT. The mean age was 55 years
(range 40 to 67), with a preponderance of male patients
(17:4). All had histological diagnoses made, with specimens
obtained at surgery (described as either a biopsy (10
patients), debulking (10 patients), or a macroscopic
clearance (1 patient). All patients had their performance
and neurological status recorded as well as standardised
assessments of quality of life, anxiety and depression.
During the first 2 cycles of treatment, enzyme (06-AGT)
and adduct (06-MeG) levels in peripheral blood samples
were measured.
For 17 of the 21 patients, there is follow up data for at
least 6 months. 2 patients had a partial response (WHO
criteria), and 1 patient had a 'significant' radiological
response - but, as is common in glioma, formal 2-
dimensional measurements were not possible because of
the diffuse nature of the tumour. The mean progression free
survival (PFS) of these patients was 527 days (613, 600, 369
days). Patients who maintained stable disease for three
months during treatment (3 patients) have a considerably
higher mean PFS to date than those who progressed on
chemotherapy (195, 230 and 343 days, mean 256 days vs 46
days). 35% of patients in the study achieved either a partial
response or stable disease. It is well established that the best
results are seen in young patients of good performance
status, in whom it is possible to remove most or all of the
tumour. Our results are compatible with this.
A previous study using dacarbazine in melanoma
demonstrated peak adduct levels 1-4 h after treatment,
with prolonged reduction in the level of AGT. The
enzyme and adduct levels are being analysed by Dr
Kyrtopoulos and will be presented with the response and
toxicity data.
No physiological morbidity was detected due specifically
to the chemotherapy (using HAD and Rotterdam ques-
tionnaires). This regimen can be given as an outpatient, with
appropriate anti-emetics.
In future studies it may be possible to schedule
methylating agents in such a way to reduce the level of
AGT to allow maximum O6-MeG formation. This may be
reflected by increased tumour response.
2.7 High dose therapy (HDT) with melphalan (M) and total
body irradiation (TBI) or busulphan (B) for Ewing's sarcoma
(ES)
JS Whelan* and RL Souhami
The London Bone Tumour Service, Meyerstein Institute of
Oncology, UCL Hospitals, London, UK.
The prognosis of metastatic or recurrent ES is poor with
conventional dose chemotherapy. Studies of HDT are
difficult because of the rarity of ES. Thus, appropriate
patients and therapy are as yet undefined. Ten patients
have been treated with HDT and either bone marrow (3
patients) or peripheral stem cell rescue (PSCR, 6) or both
(1). Median age was 16 years (range 9-30) and primary
sites were femur, 4; pelvis, 3; humerus, 1; scapula, 1;
extraosseous, thigh, 1. Lung metastases were present in 7
patients at diagnosis. Six of these patients had HDT as
consolidation of response to first line induction treatment
(3 pts) or second line therapy (3 pts). The 7th was treated
when lung metastases recurred (1st remission, 35 months).
Three further patients were treated at the time of a first
recurrence locally (1; 1st remission, 13 mos) or in the lung
(2; 1st remissions, 4 and 12 mos). Disease status at time of
HDT was: 1st remission, 5; progressive disease, 1; 2nd
remission, 4. HDT was Melphalan 110 mg/M2 and TBI (3
patients) or Busulphan, < 16 years, 600 mg/M2; > 16, 16 mg/
kg (7). Cyclophosphamide, 1.5 mg/M2 and Filgrastim 10 mg/
kg was used for PSC mobilisation. Median number of days
to neutrophils >0.5 x I09/I was 13 (range 11-26) and to
platelets >20, 19 days (10 -+50). Impaired platelet recovery
was frequent after M + B with PSCR. Other toxicities of
M+B included seizures (2 pts), haemorrhagic cystitis (1),
veno-occlusive disease (1) and pulmonary fibrosis (1). There
were no treatment related deaths. Two patients have died of
ES, 9 and 21 mos after HDT. Eight patients are alive
without evidence of progression between 1 and 41 mos
(median, 12) after HDT. Future studies will incorporate
alternative agents. Multicentre studies are needed to aid
selection of appropriate patients and thus determine any
benefit of HDT in ES.
2.8 Use of high dose chemotherapy in adult Ewing's sarcoma
and PNET
MW Verrill* and IR Judson
Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London
SW3 6JJ.
Adult patients (pts) with Ewing's Sarcoma (ES) have a poor
prognosis which is thought to be due to almost invariable
finding of bulky disease at presentation. Studies in paediatric
patients suggest that melphalan containing high dose (HD)
chemotherapy (CT) at first remission may improve survival in
this group' and there are also reports showing high
response rates in pts with a poor response to primary CT4.
We have now treated 7 adult patients with bulky or
metastatic ES with HD CT. Characteristics: median age 28
(17-42); all male; pelvis 3, thigh 1, chest wall 1, thumb 1,
unknown, 1; metastatic 4, localised 3.
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Primary Overall Time - Tune- Follow
Pt IP CT response HD CT response progression death up
1 IVAD PR M PR II months 18 m
2 IVAD NE M NE 4 m 6 m
3 IVAD PR M PR 19 m 35 m
4 IVAD NC CM PR 7 m 21 m
5 IECG PR CEM CR 4 m
6 IECG PR CEM CR 2 m
7 IECG PR CEM PR I m
IVAD= Ifosfamide Vincristine Adriamycin, IECG=Ifosamide Etoposide
Cyclophosphamide G-CSF
HD combinations: M=Melphalan, C=Carboplatin, E=Etoposide
Responses: Complete CR, Partial PR, No change NC, Not Evaluable NE.
We conclude that HD CT may produce disease
stabilisation in pts with bulky tumours who achieve only
PR after primary CT, this may lead to a survival benefit.
Based on the paediatric data we hope that those pts who
have achieved CR will show a similar trend. There is a need
for multicentre national or international studies of HDCT in
adults with Ewing's Sarcoma.
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2.9 A comparative study of subjective assessment, image
anaysis (IA) and ELISA for the qu fation of cellr CEA
levels
RCT Austin, NJ Bradley and MC Winslet
University Department ofSurgery, Royal Free Hospital
Medical School, Pond Street, London, NW3 2QG.
The use of immunocytochemistry for detection of cellular
antigen is limited by the subjective quantification of
immunostaining. Objective methods of assessment include
computer aided image analysis and enzyme linked immuno-
sorbent assay on whole cells (CELISA).
The aim of this study was to establish a CELISA for CEA
and compare the results of subjective and objective
quantification. Cytospin preparations (106 cells/ml) of two
colorectal cancer cell lines (HT29, LoVo) with variable CEA
expression, grown in the presence of augmenting agents
(Theophylline/le-2m, Butyric Acid/0.5e-3m and 5-Azacyti-
dine/le-6m) were processed by standard immunocytochemical
techniques using the primary and secondary antibodies A5B7
and RAMP for subjective/image analysis. Identical cell
preparations fixed to 96 well plates (Nunc) with 1%
glutaraldehyde were blocked with 5% NHS and stained
with A5B7 with optical density recorded at 450 nm on an
ELISA plate reader. A subjective assessment of total cytospin
(105 cells) were scored blind on a scale (0- 12). Computerised
video image analysis (Chromatic Colour Image Analysis
System) recorded signal density per cell in arbitrary
standardised unit with background standardisation.
Comparison of subject assessment and IA produced a
coefficient of determination by regression analysis (R2) of
0.415, whilst subjective analysis and CELISA produced a
regression of 0.999. IA was strongly influenced by hetero-
geneous background illumination.
Subjective assessment of immunocytochemical CEA
estimation is superior to objective image analysis and
correlates closely with the results produced by independent
standard CELISA.
2.10 Cell on moles in patients with TCC of the
bladder: solble sernn E-cadherin correlates wi predictors of
reurrence
TRL Griffiths*l.3, I Brotherick3, RI Bishop , CHW Home4,
BK Shenton3, DE Neal"3 and JK Mellon 3
Depts. of Urology, 2Cit Hospitals, Sunderland and 'Freeman
Hospital, Newcastle upon Tyne and Depts. of3Surgery and
'Pathology, University ofNewcastle, Newcastle upon Tyne,
NE2 4HH.
On newly-diagnosed superficial bladder tumours, approxi-
mately 30% are multifocal at presentation, 60-70% will
recur and 10-20% will undergo stage progression. Multi-
plicity at presentation and a positive three-month check
cystoscopy are factors associated with tumour recurrence. A
proportion of cases with tumour recurrence may be due to
dispersion of cells by mechanisms currently not well
understood. It has been suggested that decreased intercel-
lular adhesiveness favours detachment of tumour cells.
Indeed, downregulation of E-cadherin expression on bladder
tumours is associated with a reduced time to tumour
recurrence. Soluble vascular cell adhesion molecules have
been linked with angiogenesis in the rat model.
Sera from 40 patients with newly-diagnosed bladder cancer
(28 superficial tumours [pTa and pTl] and 12 muscle-invasive
tumours) and 13 control patients were assessed by ELISA to
determine the concentrations of soluble cell adhesion
molecules, sE-cadherin, sE-selectin, sVCAM-l (vascular cell
adhesion molecule-i) and sICAM-l (intercellular adhesion
molecule-l). Corresponding frozen sections of primary
tumour were stained with a monoclonal antibody to E-
cadherin, HECD-1, using standard immunohistochemistry.
Patients with bladder cancer had significantly higher
concentrations of sE-cadherin compared with the control
group (P=0.017). No difference was found between the two
groups with regard to sE-selection (P=0.403), sVCAM-1
(P=0.942) or sICAM-1 (P=0.092). Levels of sE-cadherin
were related to poor histological grade (P=0.011), number of
superficial tumours at presentation (P=0.008) and a positive
three-month check cystoscopy in superficial disease
(P=0.036). The lowest levels of sE-cadherin were found in
patients who presented with solitary low grade tumours who
had a negative three-month check cystoscopy. For those
patients with muscle-invasive disease, elevated sE-cadherin
was not related to the presence of metastatic lesions at
presentation. Abnormal E-cadherin expression on the tumour
was associated with stage (P=0.009) and grade (P=0.03). No
correlation was found between high levels of sE-cadherin in
sera and an abnormal E-cadherin staining pattern (P =0.077).
Elevated levels of sE-cadherin can be detected in sera of
patients with bladder cancer. Its association with multi-
focality at presentation and tumour recurrence suggest that it
is a serum marker with potential predictive value in
determining future tumour behaviour.
2.11 Tamoxifen inhibition of human melanoma cell invasion in
varo
LO Dewhurst*, M Wagner, IG Rennie and S MacNeil
Depts. ofMedicine, Clinical Sciences Centre, Northern General
Hospital, Sheffield, S5 7AU.
The need for tumour cells to interact with stromal
extracellular matrixc (ECM) proteins to migrate and invade,
is an area for potential pharmacological intervention. In
recent ye;ars, we have found evidence that both intracellular
calcium and calmodulin appear to play important roles in the
attachment of several normal and neoplastic cells to ECM
proteins (e.g. as summarised in MacNeil et al., 1994, Pigment
Cell Research 7, p 222).In this study, we have begun to examine the concept that
inhibition of intracellular calmodulin activity will reduce
tumour cell invasion though ECM proteins. We have initially
used Tamoxifen, a drug with both anti-oestrogen and anti-
calmodulin properties (IC50 around 2 pM - MacNeil et al.
(1993) Melanoma Research 3 p67).
Human cutaneous melanoma cells A375-SM, normal
human uveal melanocytes and dermal fibroblasts at 1.2-
1.8 x 104 cells/well were added in serum-free media to the
upper chamber of a Costar Transwell insert containing a
6.5 mm diameter polycarbonate filter with 8 pm diameter
pores the underside of this filter, being coated with 0.5 pg of
human fibronectin. The Transwells were placed in 24 well
plates containing serum-free media and were cultured for
20 h with or without Tamoxifen. Trypsin/EDTA was used to
remove cells from the underside of the filter and bottom of
the 24 well, and from the upper chamber and upper surface
of the filter. The invaded and non-invaded cells were then
counted and % invasion calculated.
Under these conditions, fibroblasts were found to be non-
invasive (in 3 out of 3 experiments), melanocytes found to be
4.7+2.66% (n=3) invasive and A375-SM were 18.5+4.2%
(n = 8). Tamoxifen significantly reduced both melanocyte and
melanoma cell invasion with 50% reduction of invasion
occuring at 0.4+0.2 pM (n = 5). The concentrations of
Tamoxifen were not associated with any direct cytotoxic
effect of the drug on the cells.
We conclude that Tamoxifen can reduce the ability of
both normal (melanocyte) and neoplastic (melanoma) cells to
interact with and invade through fibronectin. Such an action
of Tamoxifen may be very relevant to its recently reported
synergistic actions with other chemotheraputic agents in
melanoma. It now needs to be determined whether
Tamoxifen is acting as an anti-oestrogen or calmodulin
antagonist.
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2.12 Cycfin Dl expression and response to tamoxifen treatment
for metastatic breast cancer
Diana M Barnes, Cheryl E Gillett, P Smith and RD Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London.
Cyclin Dl is a cell cycle associated protein active in the GI
phase of the cell cycle. Amplification of the gene is found in
approximately 20% of mammary carcinomas and immuno-
histochemistry has revealed that over-expression of cyclin Dl
protein occurs more frequently. It is present in 40-50% of
breast cancers suggesting oncogenic activity which could be
associated with poor clinical outcome. Surprisingly, we found
the reverse to be true; in primary breast cancer the highest
levels of cyclin Dl expression occur in well differentiated ER
positive tumours, usually associated with a good prognosis.
We have also investigated the relationship between cyclin Dl
protein expression and response to first line tamoxifen
treatment for metastatic disease in 149 women. Response to
treatment was assessed in a standard manner, according to
UICC criteria and was available on all patients. Women
whose response was unassessable were excluded from the
study. 95 (64%) of cases overexpressed cyclin DI, 78 (82%)
were ER positive. Response (complete/partial) was seen in 55
(71%) of these double positive tumours. Conversely tumours
which were negative for both proteins had only an 8%
chance of responding. Tumours which were positive for only
one of the proteins had an intermediate response rate
(X2=31.97, p<0.0001), suggesting that immunohistochemi-
cal staining for cyclin Dl could be a useful adjunct to the
measurement in ER in identifying women who are likely to
respond to endocrine treatment. Furthermore, these results
pose interesting questions concerning the role of cyclin Dl in
the biology of breast cancer.